GlaxoSmithKline won U.S. FDA approval for Tykerb, a once-daily pill for the treatment of advanced breast cancer in patients with HER-2 positive breast cancer who were unresponsive to Genentech’s Herceptin. Tykerb will be used in combination with Roche’s Xeloda.
This is the first of three or four oncology products that GSK hopes to launch in the next 2 or 3 years (depending on who is counting and the likelihood of the approval). In 2005 (the last year for which I could find data), GSK is nowhere to be found on the list of top oncology companies. So this is a good step forward for GSK.
